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Neurofibromatosis type 1 is a multisystemic disease. It may manifest as abnormalities of the nervous tissue, bones, soft tissue, or
skin. Autoimmune disease associated with NF1 can be seen. Diabetes mellitus is rarely seen in association with NF1. Here, we report
a case with established NF1 who also had a diagnosis of diabetes mellitus.
1. Introduction
Neurofibromatosis type 1 (NF1) is one of the most common
autosomal dominant conditions affecting ectodermal and
mesodermal tissues, occurring with an estimated incidence
of 1 in 2,500 to 3,000 individuals independent of ethnicity,
race, and gender [1]. Von Recklinghausen described NF1
in detail in a case report published in 1882, but because
of the varied presentation and pleiotropic nature of the
disease, formal diagnostic criteria were established in 1987
and updated in 1997 by the National Institutes of Health
Consensus Development Conference [2]. It is well known
that patients with neurofibromatosis show an increased
incidence of various neoplasms, most of these being tumors
of neural crest origin including neurofibromas, leiomyomas,
ganglioneuromas, paragangliomas, and carcinoids, but it has
also been related to small bowel adenocarcinoma, pancreatic
endocrine malignant tumor, and neurofibromatosis of the
colon and urinary bladder.
Diabetes mellitus is rarely seen in association with NF1.
Two childrenwith diabetesmellitus associatedwithNF1 cases
have been reported so far [3, 4]. Here, we report a case
with established NF1 who also has a diagnosis with diabetes
mellitus.
2. Case Report
A 9-year-old boy was admitted to the hospital with a his-
tory of polydipsia, polyuria, and enuresis nocturna for the
last month. He was the first child of nonconsanguineous
parents. His birth history was uneventful. His birth weight
was 4000 gr (SDS: 0.95). His uncle has type 2 diabetes.
On his physical examination, weight was 25 kg (SDS: 0.38),
body mass index was 13,52 kg/m2 (SDS: 1.80), height was
136 cm (SDS: 1.42), blood pressure was 95/60mmHg, and
pulse rate was 95 bpm and rhythmic. His dermatological
examination revealed multiple café-au-lait spots (>9) of 1–
5 cm in diameter. He had two plexiformneurofibromas on his
neck examination. Laboratory examination revealed a blood
glucose level of 447mg/dL; urinalysis revealed glucosuria and
ketonuria; his blood ketone level was 2mmol/L (normal level
< 0.8). Acidosis was not detected on his concurrent blood
gases analyses. Liver and renal functionswere normal. Insulin
level was <2 uU/mL (normal level 2.6–24.9), C-peptide level
was 0.473 ng/mL (normal level 1.1–5), and HbA1c was 10.7%
(normal range 4.6–6.4%). His thyroid function tests were
normal. Islet cell antibodies (ICA) were 0.147U/mL (normal
range 0–1.1); insulin-associated antigen-2 antibody (IAA)was
<0,032 (normal range < 0.4). His thyroid and celiac antibod-
ies investigationwas negative.Thepatientwas diagnosedwith
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neurofibromatosis type 1 and diabetes mellitus type 1. Insulin
treatment was initiated, and normoglycemia was maintained
on 0.8 units of insulin/kg/day. Later, the patient underwent
further investigations to search for other characteristics of
neurofibromatosis. Eye examination revealed no iris Lisch
nodules. Osseous lesionswere not detected on skeletal survey.
Cranial magnetic resonance imaging (MRI) showed multiple
hyperintense signal abnormalities in T2-weighted sequences.
Abdominal ultrasonography and MRI were normal. Blood
somatostatin level was 16 pg/mL (normal 0−26). On his
regular followup, HbA1c level decreased to 6.9%.
3. Discussion
NF1, previously known as von Recklinghausen’s disease,
is a relatively common autosomal dominant disease [2].
The specific gene maps to chromosome 17q11.2. Clinical
manifestations of NF1 include cafe-au-lait spots, freckling,
generalized cutaneous neurofibroma, Lisch nodules, short
stature, optic glioma, and CNS tumors. NF1 patients have
increased risk of developing malignancies. They have a
high spontaneous mutation rate, and mutations in tumor
suppressor genes play an important role in the development
of tumors [5]. The most common cause of death is CNS
tumors.
There are few reports of NF1 patients associated with
autoimmune diseases. The reported autoimmune diseases
associated with NF1 are as follows: systemic lupus erythe-
matosus, multiple sclerosis, membranous glomerulonephri-
tis, IgA nephropathy, mixed connective tissue disease, juve-
nile arthritis, autoimmune hemolytic anemia, bullous pem-
phigoid, vitiligo, and autoimmune thyroiditis [2, 5].
Diabetes mellitus is rarely seen in association with NF1.
It is attributed to the occurrence of somatostatinomas in
the pancreas and the duodenum [3]. Somatostatinomas are
rare endocrine tumors. They derive from the somatostatin-
producing delta cells of the pancreas or the endocrine cells
of the digestive tract and may be sporadic (93.1%) or familial
(6.9%) in association with NF1, multiple endocrine neoplasia
type 1 (MEN 1), and Von Hippel-Lindau syndrome [6].
The classic somatostatinoma syndrome, diabetes mellitus,
diarrhea/steatorrhoea and cholelithiasis, typically occurs in
pancreatic tumors, whereas duodenal tumors most often
present with obstructive symptoms. These rare neoplasms
have been reported only in adult and elderly patients. Since
the clinical symptoms are often variable and nonspecific,
great many somatostatinomas are “incidentalomas” found
during cholecystectomy or in the course of gastrointestinal
imaging studies. CT,MRI, selective arteriography of the celiac
tripod, and endoscopic retrograde cholangiopancreatogra-
phy are useful diagnostic tools for correctly locating the
tumor [6]. Diagnosis may be confirmed by measuring the
fasting plasmatic hormone concentration by means of the
radioimmunoassay method. If the plasmatic basal levels of
somatostatin do not indicate values that are at least three
times the normal concentration, diagnostic tests, both stim-
ulatory (with tolbutamide, calcium/pentagastrin, or secretin)
and inhibitory (with diazoxide), can be performed.
Our patient was diagnosed with NF1 according to formal
diagnostic criteria and diabetes mellitus type 1. He had
multiple café-au-lait spots and two plexiform neurofibro-
mas. Two or more clinical features signify the presence of
NF1 in a patient [2]. We performed abdominal MRI and
ultrasonography to detect any abnormality associated with
NF1 and somatostatinoma. Although abdominal imagingwas
negative, we checked blood somatostatin level to exclude
somatostatinoma. Somatostatin level was found within nor-
mal range. Two children with diabetes mellitus associated
with NF1 cases have been reported. Zaka-ur-Rab and Chopra
reported a 9-year-old-boy known to have NF1 since birth.
He presented with polydipsia, polyuria, and polyphagia for
the last 3 months. His blood glucose was 830mg/dL. Urine
examination showed specific gravity of 1.040, glucosuria of
4+, and traces of ketone bodies.Thepatientwas put on insulin
therapy, and normoglycemia was maintained on 0.8 units
of insulin/kg. They had searched for somatostatinoma but
did not mention anything about autoantibody against the
pancreas. The second patient was reported by Kamoun et al.
in 2009.The patient was a 15-year-old boy. He presented with
polyuria, polydipsia, and weight loss of a few weeks’ duration
and vomitingwith abdominal pain for the last 24 h.His family
history was positive for NF1. His blood glucose level was
360mg/dL, and he had a metabolic acidosis. Urine examina-
tion demonstrated glycosuria (4+) and ketonuria (3+). Fol-
lowing initial resuscitation, the patient commenced subcu-
taneous insulin, 0.8 units/kg/24 h. Glutamic acid decarboxy-
lase (GAD) antibodies were positive (481UI/mL, reference
range < 10UI/mL). All the other autoantibodies, including
insulin-associated antigen-2 antibody (IA-2), islet cell anti-
bodies (ICA), antinuclear, antithyroid peroxidase, antithy-
roglobulin, and antiadrenal antibodies were undetectable.
Reported NF1 with diabetes patients, including our
patient, were all male. This may be coincidental. One of the
reported patients had GAD antibody, but the other did not.
Our patient was searched for autoimmunity, but no positive
antibody could be found. The pathological process causing
diabetes mellitus is not yet clear. The NF1 gene is located
on chromosome 17q11.2. Neurofibromin, the product of the
nonmutated gene, has the activity of a GTPase-activating
protein and is capable of downregulating the cellular p21-
ras protooncogene. The loss of neurofibromin function may
lead to uncontrolled cell growth or tumor formation, which
may lead to increased tumor formation in patients with NF1
[7, 8]. Furthermore, abnormal neurofibromin production
suppresses Fas ligand expression.This may prevent apoptosis
of CD4+ T cells, which is important in the development
of autoimmunity [1]. Decreased T cell apoptosis due to
abnormal neurofibromin production may be an underlying
factor for the development of the autoimmune diseases.
As the number of reports on the coexistence of NF1 and
autoimmune diseases increases, an association rather than a
coincidence becomes more likely.
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